Open-house rebate agreement for Rasagilin
Titre original de l'avis
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Rasagilin, ATC N04BD02
Score d'opportunité
Pourquoi ce score ?
Opportunité
62 / 100
Complexité
48 / 100
Facteurs de risque
Paper submissions are only timely if the complete original documents arrive by the 10th of the month after prior transm...
The notice requires a signed declaration of reliability and indicates that only pharmaceutical companies can contract;...
Submission deadline in 7 days
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Aperçu
Moderate opportunityFaits clés
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Oct 2026
- Non-exclusive open-house rebate agreements for Rasagilin, ATC N04BD02.
- Supply of pharmaceutical products under fixed, pre-defined contract terms.
Afficher le résumé complet
This is an open-house pharmaceutical supply arrangement for Rasagilin (ATC N04BD02) offered by AOK Bayern. It is not a competitive award procedure: the notice states that all interested pharmaceutical companies meeting the stated suitability requirement can join on identical, non-negotiable terms. The contract period runs from 01.11.2024 to 31.10.2026, with the latest possible contract conclusion on 05.09.2026. No contract value is stated. Submission is possible electronically with a qualified electronic signature or in paper form, and the notice requires German-language submission or German translation for non-German documents.
Risques
Paper submissions are only timely if the complete original documents arrive by the 10th of the month after prior transm...
The notice requires a signed declaration of reliability and indicates that only pharmaceutical companies can contract;...
Submission deadline in 7 days
L'analyse peut être incomplète
Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.
Exigences clés
Technical
- The signatory's authority must be evidenced by the commercial register extract, otherwise a power of attorney must be provided.
Administrative
- Submit a signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit).
- Submit the completed and signed contract and the completed and signed annex 'Festlegung der vertragsgegenständlichen Arzneimittel'.
Acheteur
Localisation
München, DEU
Site web
Profil acheteur
Identifiant
DE811695320
Activité
Health
Lots (1)
LOT-0001
Open-house rebate agreement for Rasagilin
Single lot covering non-exclusive open-house rebate agreements for the medicinal product Rasagilin, ATC N04BD02. The lot is for pharmaceutical products (CPV 33600000) and performance is in Germany, specifically DE212. The notice text indicates the contract terms are fixed in advance and not individually negotiable.
Localisation
Durée
Catégorie
Date limite
Détails des critères
Siehe kurze Beschreibung
Note sur la valeur
Afficher les données TED originales
Titre original du lot
Open house Arzneimittelrabattverträge Rasagilin, ATC N04BD02
Description TED originale
Siehe kurze Beschreibung
Détails de la procédure
- Date de publication
- 16 Sep 2024
- Langues
- German
Métadonnées de référence
- Base juridique
- 32014L0024
Identifiants de référence
- ID de l'appel d'offres
- 556500-2024
Documents (2)
Appels d'offres similaires
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Score d'opportunité
Pourquoi ce score ?
Opportunité
62 / 100
Complexité
48 / 100
Facteurs de risque
Paper submissions are only timely if the complete original documents arrive by the 10th of the month after prior transm...
The notice requires a signed declaration of reliability and indicates that only pharmaceutical companies can contract;...
Submission deadline in 7 days
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications